When was Tonix Pharma founded?

Tonix Pharma was founded in 2007 and raised its 1st funding round 3 years after it was founded.

Where is Tonix Pharma located?

Tonix Pharma is headquartered in New York City, United States.

How many employees does Tonix Pharma have?

As of Aug 31, 2026, the latest employee count at Tonix Pharma is 181.

Is Tonix Pharma a funded company?

Tonix Pharma is a funded company, having raised a total of $4.45M across 12 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 17, 2010.

When was the latest funding round of Tonix Pharma?

Tonix Pharma's latest funding was a $***** Grant (prize money) round on Apr 03, 2025, with participation from 1 investor.

What is the annual revenue of Tonix Pharma?

Annual revenue of Tonix Pharma is between $10M and $50M as on Dec 31, 2025

Where does Tonix Pharma rank among its competitors?

Tonix Pharma ranks 83rd amongst 4451 active competitors, of which 1475 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Tonix Pharma?

Tonix Pharma's top competitors include Jazz Pharmaceuticals, BridgeBio and BeiGene. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Tonix Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Tonix Pharma is a public company based in New York City (United States), founded in 2007 by Seth Lederman. It operates as a Developer of next-generation medicines for CNS and immunological disorders. Tonix Pharma has raised $4.45M in funding. The company has 4451 active competitors, including 1475 funded and 1047 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BridgeBio and BeiGene.

Company Details

Developer of next-generation medicines for CNS and immunological disorders. The lead product of the company is TNX-601 (tianeptine oxalate), for the treatment of Post-traumatic stress disorder (PTSD), and TNX-801 for horsepox virus.

Website: www.tonixpharma.com/
Social

Key Metrics

Founded Year

2007

Location

New York City, United States

Stage

Public

Total Funding

$4.45M in 12 rounds

Latest Funding Round

Grant (prize money), Apr 03, 2025, $*****

Investors

Westwicke & 3 more

Ranked

83^rd among 4451 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

181 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3353 more

Exit Details

Public

View Tonix Pharma's full profile

Tonix Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tonix Pharmaceuticals Holding Corp CIN: 26-1434750 , United States, Active	Dec 31, 2006	-	73 (As on Dec 31, 2022)	-
Tonix Pharmaceuticals Holding Corp. CIN: 1430306 , United States, Active		$10M - $50M (As on Dec 31, 2025)	117 (As on Mar 31, 2023)	-

Tonix Pharma got listed on Nov 16, 2012.

Click here to take a look at Tonix Pharma's IPO in detail

Tonix Pharma has raised a total funding of $4.45M over 12 rounds. Its first funding round was on Aug 17, 2010. Its latest funding round was a Grant (prize money) round on Apr 03, 2025 for $*****. 1 investor participated in its latest round. Tonix Pharma has 4 institutional investors.

Here is the list of recent funding rounds of Tonix Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2025	7134703	Grant (prize money)	8256514	1129508	8296389	2844896
Feb 26, 2025	8093747	Grant (prize money)	5497052	1196068	3112454	HHS
Oct 25, 2022	7896443	Post IPO	3029813	5151459	9465133	1043249

Access funding benchmarks and valuations. Sign up today!

View details of Tonix Pharma's funding rounds and investors

The founders of Tonix Pharma is Seth Lederman.

Here are the details of Tonix Pharma's key team members:

Seth Lederman: Co-Founder & CEO of Tonix Pharma.

View details of Tonix Pharma's Founder profiles and Board Members

Tonix Pharma's employee count trend

Tonix Pharma has 181 employees as of Aug 26. Here is Tonix Pharma's employee count trend over the years:

Uncover Tonix Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tonix Pharma include Jazz Pharmaceuticals, BridgeBio and BeiGene. Here is the list of Top 10 competitors of Tonix Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
5th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
6th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
7th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
9th	CareDx 1998, Brisbane (United States), Public	Developer of medical solutions for transplant patients	$138M	Intel, Integral Capital Partners & 24 others	73/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
83rd	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	66/100